IP Life Sciences and Advanced Materials

Given the competitive nature of the Life Sciences and Advanced Technology industry, every company operating in those fields needs to manage its intellectual property (IP) to facilitate continued innovation and maintain or grow market share.

For over three decades, Johnson & Johnson has trusted us as a strategic partner in protecting innovation. We support the company’s patent prosecution efforts across a broad range of technologies, including medical and surgical devices as well as small- and large-molecule therapeutics. Beyond prosecution, we provide strategic counseling on patent and technology matters, including portfolio management, product clearance, and competitive patent analysis.
To protect combination products and drug regimens in light of inherent bias in the law against such subject matter, we devised exclusivity strategies for J&J’s darunavir patent portfolio and analyzed patent applications and clinical data, developing sophisticated legal arguments for patentability.
We represented Teva Pharmaceuticals in its exclusivity strategies for TREANDA and BENDEKA, used to treat people with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. We also helped Teva with exclusivity strategies and patent portfolio development for AUSTEDO, used to treat chorea.
We developed patent portfolio strategies for Tyra Pharmaceuticals, and when the company went public, its IPO raised more than $170 million. We did the same for Prelude Therapeutics, which we have represented since its inception. Prelude’s IPO was also very successful.
Teleflex Inc. manufactures a wide array of medical technologies (including devices) in the vascular, respiratory, cardiac and anesthesia areas, and its products are used in critical care and surgery. We handle all of the company’s patent and trademark prosecution matters across nearly 30 divisions.
We manage global patent portfolio for a first-in-class anti-FcRn antibody and for a bispecific monoclonal antibody approved for the treatment of non-small lung cancer. These portfolios span compositions, formulations, and therapeutic methods across multiple indications. Our work includes coordinating international prosecution, developing technical arguments addressing novel dosing and mechanism-of-action challenges, preparation of submissions to foreign regulatory agencies, and securing lifecycle extensions, including patent term extension strategies tied to regulatory approvals.
We support prosecution of patent applications directed to anti-CD38 antibody therapies, including claims to clinically validated formulations and combination regimens. Our work focuses on advancing protection for evolving treatment paradigms and combination therapies in oncology.
We handle a developing portfolio directed to anti–kallikrein-2 antibody technologies, including immunoconjugates and therapeutic applications for prostate cancer. Our work includes advancing early-stage global filings to build protection around novel antigen-targeting strategies and their therapeutic uses.
We represent agriculture company Syngenta in ex parte appeals before the PTAB, with a strong track record of securing reversals or partial reversals for the client.